BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's ...

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started ...

For more than six decades of artistic creation, Robert Rauschenberg worked in a wide variety of mediums, such as painting, sculpture, prints, photography and performance. Now showing at M+ is a major ...